
What is claimed is:

1. A compound of Formula (IX):



(IX)

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X^3 is N or CR^3;

X^6 is N or CR^6;

R^9 is CH_3 or CN;

R^3, R^4, R^5, and R^6 are each independently selected from H, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-14 membered heteroaryl)-C_{1-4} alkyl-, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, CN, NO_2, OR^a, SR^a, $NHOR^a$, $C(O)R^a$, $C(O)NR^aR^a$, $C(O)OR^a$, $OC(O)R^a$, $OC(O)NR^aR^a$, NHR^a, NR^aR^a, $NR^aC(O)R^a$, $NR^aC(O)OR^a$, $NR^aC(O)NR^aR^a$, $C(=NR^a)R^a$, $C(=NR^a)NR^aR^a$, $NR^aC(=NR^a)NR^aR^a$, $NR^aS(O)R^a$, $NR^aS(O)_2R^a$, $NR^aS(O)_2NR^aR^a$, $S(O)R^a$, $S(O)NR^aR^a$, $S(O)_2R^a$, and $S(O)_2NR^aR^a$, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-14 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^3, R^4, R^5, and R^6 are each optionally substituted with 1, 2, 3, or 4 R^b substituents, with the proviso that at least one of R^3, R^4, R^5 and R^6 is other than H;

each R^7 is independently selected from H and halo;

or two adjacent R^7 substituents on the phenyl ring, taken together with the atoms to which they are attached, form a fused 2,3-dihydro-1,4-dioxin-6-yl ring;

each R^a is independently selected from H, CN, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-,

C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^a are each optionally substituted with 1, 2, 3, 4, or 5 R^d substituents;

each R^d is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, halo, C_{6-10}aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, CN, NH_2, $NHOR^e$, OR^e, SR^e, $C(O)R^e$, $C(O)NR^eR^e$, $C(O)OR^e$, $OC(O)R^e$, $OC(O)NR^eR^e$, NHR^e, NR^eR^e, $NR^eC(O)R^e$, $NR^eC(O)NR^eR^e$, $NR^eC(O)OR^e$, $C(=NR^e)NR^eR^e$, $NR^eC(=NR^e)NR^eR^e$, $NR^eC(=NOH)NR^eR^e$, $NR^eC(=NCN)NR^eR^e$, $S(O)R^e$, $S(O)NR^eR^e$, $S(O)_2R^e$, $NR^eS(O)_2R^e$, $NR^eS(O)_2NR^eR^e$, and $S(O)_2NR^eR^e$, wherein the C_{1-6} alkyl, C_{1-6}haloalkyl, C_{6-10}aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^d are each optionally substituted with 1-3 independently selected R^h substituents;

each R^b substituent is independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, CN, OH, NH_2, NO_2, $NHOR^c$, OR^c, SR^c, $C(O)R^c$, $C(O)NR^cR^c$, $C(O)OR^c$, $OC(O)R^c$, $OC(O)NR^cR^c$, $C(=NR^c)NR^cR^c$, $NR^cC(=NR^c)NR^cR^c$, NHR^c, NR^cR^c, $NR^cC(O)R^c$, $NR^cC(O)OR^c$, $NR^cC(O)NR^cR^c$, $NR^cS(O)R^c$, $NR^cS(O)_2R^c$, $NR^cS(O)_2NR^cR^c$, $S(O)R^c$, $S(O)NR^cR^c$, $S(O)_2R^c$ and $S(O)_2NR^cR^c$; wherein the C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^b are each further optionally substituted with 1-3 independently selected R^d substituents;

each R^c is independently selected from H, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-,

C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^c are each optionally substituted with 1, 2, 3, 4, or 5 R^f substituents;

each R^f is independently selected from C_{1-4} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, halo, CN, $NHOR^g$, OR^g, SR^g, $C(O)R^g$, $C(O)NR^gR^g$, $C(O)OR^g$, $OC(O)R^g$, $OC(O)NR^gR^g$, NHR^g, NR^gR^g, $NR^gC(O)R^g$, $NR^gC(O)NR^gR^g$, $NR^gC(O)OR^g$, $C(=NR^g)NR^gR^g$, $NR^gC(=NR^g)NR^gR^g$, $S(O)R^g$, $S(O)NR^gR^g$, $S(O)_2R^g$, $NR^gS(O)_2R^g$, $NR^gS(O)_2NR^gR^g$, and $S(O)_2NR^gR^g$; wherein the C_{1-4} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^f are each optionally substituted with 1, 2, 3, 4, or 5 R^n substituents;

each R^n is independently selected from C_{1-4} alkyl, C_{1-4} haloalkyl, halo, CN, R^o, $NHOR^o$, OR^o, SR^o, $C(O)R^o$, $C(O)NR^oR^o$, $C(O)OR^o$, $OC(O)R^o$, $OC(O)NR^oR^o$, NHR^o, NR^oR^o, $NR^oC(O)R^o$, $NR^oC(O)NR^oR^o$, $NR^oC(O)OR^o$, $C(=NR^o)NR^oR^o$, $NR^oC(=NR^o)NR^oR^o$, $S(O)R^o$, $S(O)NR^oR^o$, $S(O)_2R^o$, $NR^oS(O)_2R^o$, $NR^oS(O)_2NR^oR^o$, and $S(O)_2NR^oR^o$;

each R^g is independently selected from H, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- of R^g are each optionally substituted with 1-3 R^p substituents;

each R^p is independently selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{1-4} haloalkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl, wherein the C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl, , wherein the C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5- or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl of R^p is optionally substituted with 1, 2 or 3 R^q substituents;

or any two R^a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R^h substituents independently selected from C_{1-6} alkyl, C_{3-10} cycloalkyl, 4-7 membered heterocycloalkyl, C_{6-10} aryl, 5-6 membered heteroaryl, C_{6-10} aryl-C_{1-4}alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-6 membered heteroaryl)-C_{1-4} alkyl-, (4-7 membered heterocycloalkyl)-C_{1-4} alkyl-, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, CN, OR^i, SR^i, $NHOR^i$, $C(O)R^i$, $C(O)NR^iR^i$, $C(O)OR^i$, $OC(O)R^i$, $OC(O)NR^iR^i$, NHR^i, NR^iR^i, $NR^iC(O)R^i$, $NR^iC(O)NR^iR^i$, $NR^iC(O)OR^i$, $C(=NR^i)NR^iR^i$, $NR^iC(=NR^i)NR^iR^i$, $S(O)R^i$, $S(O)NR^iR^i$, $S(O)_2R^i$, $NR^iS(O)_2R^i$, $NR^iS(O)_2NR^iR^i$, and $S(O)_2NR^iR^i$, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4-7 membered heterocycloalkyl, C_{6-10} aryl, 5-6 membered heteroaryl, C_{6-10} aryl-C_{1-4}alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-6 membered heteroaryl)-C_{1-4} alkyl-, and (4-7 membered heterocycloalkyl)-C_{1-4} alkyl- of R^h are each further optionally substituted by 1, 2, or 3 R^j substituents;

each R^j is independently selected from C_{3-6} cycloalkyl, C_{6-10} aryl, 5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, $NHOR^k$, OR^k, SR^k, $C(O)R^k$, $C(O)NR^kR^k$, $C(O)OR^k$, $OC(O)R^k$, $OC(O)NR^kR^k$, NHR^k, NR^kR^k, $NR^kC(O)R^k$, $NR^kC(O)NR^kR^k$, $NR^kC(O)OR^k$, $C(=NR^k)NR^kR^k$, $NR^kC(=NR^k)NR^kR^k$, $S(O)R^k$, $S(O)NR^kR^k$, $S(O)_2R^k$, $NR^kS(O)_2R^k$, $NR^kS(O)_2NR^kR^k$, and $S(O)_2NR^kR^k$,wherein the C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy of R^j are each optionally substituted with 1, 2 or 3 independently selected R^q substituents;

or two R^h groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl taken together with the carbon atom to which they attach form a C_{3-6} cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N and S;

or any two R^c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R^h substituents;

or any two R^e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R^h substituents;



or any two R^g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R^h substituents;

or any two R^o substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R^h substituents;

each R^e, R^i, R^k, R^o or R^p is independently selected from H, C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{1-4} haloalkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl, wherein the C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl of R^e, R^i, R^k, R^o or R^p are each optionally substituted with 1, 2 or 3 R^q substituents;

each R^q is independently selected from OH, CN, -COOH, NH_2, halo, C_{1-6}haloalkyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C_{3-6}cycloalkyl, NHR^{12}, $NR^{12}R^{12}$, and C_{1-4} haloalkoxy, wherein the C_{1-6} alkyl, phenyl, C_{3-6}cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R^q are each optionally substituted with halo, OH, CN, -COOH, NH_2, C_{1-4}alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, phenyl, C_{3-10} cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl; and

each R^{12} is independently C_{1-6} alkyl.

2. The compound of claim **1**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the moiety:  is :  .

3. The compound of claim **1** or **2**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein X^3 is CH, R^5 is H and X^6 is CR^6.

4. The compound of claim **1** or **2**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein X^3 is CH and X^6 is CR^6.

5. The compound of any one of claims **1-4**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 is $–CH_2-R^b$.

6. The compound of any one of claims **1-4**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 is 2-hydroxyethylaminomethyl.

7. The compound of any one of claims **1-4**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 is 2-hydroxyethylaminomethyl, 2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl or (R)-2-carboxypiperidin-1-ylmethyl.

8. The compound of any one of claims **1-2** and **4-8**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^5 is $–CH_2-R^b$.

9. The compound of any one of claims **1-2** and **4-7**, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^3 and R^5 are each H.

10. The compound of claim **5** or **8**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^b is $–NHR^c$.

11. The compound of claim **5** or **8**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^b is $–NR^cR^c$.

12. The compound of claim **10** or **11**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^c is C_{1-4} alkyl optionally substituted with a R^d substituent.

13. The compound of claim **10** or **11**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein two R^c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R^h substituents.

14. The compound of claim **10** or **11**, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein two R^c substituents together with the nitrogen atom to which they are attached form a 6-membered heterocycloalkyl substituted with 1 R^h substituent.

15. The compound of any one of claims **1-14** or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 and R^5 are each independently selected from 2-hydroxyethylaminomethyl, 2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl, (R)-2-carboxypiperidin-1-ylmethyl, (3-cyanophenyl)methoxy, cyanomethoxy, 2-cyanoethoxy, 3-cyanopropoxy, 2-morpholino-4-ylethoxy and pyridin-2-ylmethoxy.

16. The compound of claim **1**, wherein the compound is selected from:

(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid;

2-({[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)ethanol;

(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid;

2-({[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)ethanol;

(2S)-1-{[2-(2-cyanobiphenyl-3-yl)-7-methyl-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid;

3-(5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-1,3-benzoxazol-2-yl)biphenyl-2-carbonitrile;

(2S)-1-({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid;

2-[({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl-1,3-benzoxazol-5-yl}methyl)amino]ethanol;

(2S)-1-({2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-7-methyl-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid; and

2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-1,3-benzoxazol-2-yl)benzonitrile; or

a pharmaceutically acceptable salt thereof.

17. The compound of claim **1**, wherein the compound is selected from:

(2*S*)-1-{[6-(cyanomethoxy)-2-(2-methylbiphenyl-3-yl)-1, 3-benzoxazol-5-yl]methyl} piperidine-2-carboxylic acid;

{[5-{[(2-hydroxyethyl)amino]methyl}-2- (2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}acetonitrile;

(2S)-1-{[6-(3-cyanopropoxy)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl} piperidine-2-carboxylic acid;

3-({[5-{[(2-hydroxyethyl)amino]methyl}-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}methyl)benzonitrile;

2-({[2-(2-methylbiphenyl-3-yl)-6-(pyridin-2-ylmethoxy)-1,3-benzoxazol-5-yl]methyl} amino)ethanol;

2-({[6-methoxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)ethanol;

2-({[2-(2-methylbiphenyl-3-yl)-6-(2-morpholin-4-ylethoxy)-1,3-benzoxazol-5-yl]methyl}amino)ethanol;

4-{[5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}butanenitrile;

(2S)-1-({6-(cyanomethoxy)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid;

(2S)-1-{[2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-6-(cyanomethoxy)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid;

(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]methyl}piperidine-2-carboxylic acid; and

[(2-(2'-fluoro-2-methylbiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}-1,3-benzoxazol-6-yl)oxy]acetonitrile; or

a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of any of claims **1-15** or a pharmaceutically acceptable salt or a stereoisomer thereof, or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

19. A compound of any of claims **1-15**, or a pharmaceutically acceptable salt or a stereoisomer thereof, or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof, for use in the inhibition of growth of tumor cells *in vitro*.

20. A compound of any of claims **1-15**, or a pharmaceutically acceptable salt or a stereoisomer thereof; or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof; or a composition of claim **18**, for use in the treatment of a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, wherein the disease or disorder is a viral infection or cancer.

21. The compound or composition for use of claim **20**, wherein the disease or disorder is cancer.

22. The compound or composition for use of claim **21**, wherein the cancer is selected from bone cancer, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary central nervous system (CNS) lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T–cell lymphoma, environmentally induced cancers including those induced by asbestos, melanoma, metastatic malignant melanoma, renal cancer, clear cell renal cell carcinoma, prostate cancer, breast cancer, colon cancer, lung cancer, non-small cell lung cancer, solid tumors, hepatic cancer, gastric cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, hematological cancers, lymphoma, leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia, (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (NHL), relapsed or refractory

non-Hodgkin lymphoma (NHL), recurrent follicular non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, and multiple myeloma.

23. The compound or composition for use of claim **21**, wherein the cancer is a metastatic cancer that expresses PD-L1.

24. The compound or composition for use of claim **21**, wherein the cancer is lung cancer.

25. The compound or composition for use of claim **21**, wherein the cancer is non-small cell lung cancer.

26. The compound or composition for use of claim **21**, wherein the cancer is hepatic cancer.

27. The compound or composition for use of claim **21**, wherein the cancer is melanoma.

28. The compound or composition for use of claim **21**, wherein the cancer is cancer of the bladder.

29. The compound or composition for use of claim **21**, wherein the cancer is cancer of the urethra.

30. The compound or composition for use of claim **21**, wherein the cancer is renal cancer.

31. The compound or composition for use of claim **21**, wherein the cancer is clear cell renal cell carcinoma.

32. The compound or composition for use of claim **21**, wherein the cancer is squamous cell cancer.

33. A compound of any of claims **1-15**, or a pharmaceutically acceptable salt or a stereoisomer thereof; or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt

thereof; or a composition of claim **18**, for use in the enhancement, stimulation and/or increase of the immune response in a patient.

34. Use of a compound of any of claims **1-15** or a pharmaceutically acceptable salt or a stereoisomer thereof, or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of growth of tumor cells *in vitro.*

35. Use of a compound of any of claims **1-15**, or a pharmaceutically acceptable salt or a stereoisomer thereof; or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof; or a composition of claim **18**, in the manufacture of a medicament for the treatment of a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, wherein the disease or disorder is a viral infection or cancer.

36. The use of claim **35**, wherein the disease or disorder is cancer.

37. The use of claim **36**, wherein the cancer is selected from bone cancer, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary central nervous system (CNS) lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T–cell lymphoma, environmentally induced cancers including those induced by asbestos, melanoma, metastatic malignant melanoma, renal cancer, clear cell renal cell carcinoma, prostate cancer, breast cancer, colon cancer, lung cancer, non-small cell lung cancer, solid tumors, hepatic cancer, gastric cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, hematological cancers, lymphoma, leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia, (AML),

chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (NHL), relapsed or refractory non-Hodgkin lymphoma (NHL), recurrent follicular non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, and multiple myeloma.

38. The use of claim **36**, wherein the cancer is a metastatic cancer that expresses PD-L1.

39. The use of claim **36**, wherein the cancer is lung cancer.

40. The use of claim **36**, wherein the cancer is non-small cell lung cancer.

41. The use of claim **36**, wherein the cancer is hepatic cancer.

42. The use of claim **36**, wherein the cancer is melanoma.

43. The use of claim **36**, wherein the cancer is cancer of the bladder.

44. The use of claim **36**, wherein the cancer is cancer of the urethra.

45. The use of claim **36**, wherein the cancer is renal cancer.

46. The use of claim **36**, wherein the cancer is clear cell renal cell carcinoma.

47. The use of claim **36**, wherein the cancer is squamous cell cancer.

48. Use of a compound of any of claims **1-15**, or a pharmaceutically acceptable salt or a stereoisomer thereof; or a compound of claim **16** and **17**, or a pharmaceutically acceptable salt thereof; or a composition of claim **18**, in the manufacture of a medicament for the enhancement, stimulation and/or increase of the immune response in a patient.